Progesterone supplementation in women with threatened miscarriage: narrative review
Abstract
The effectiveness of progesterone supplementation in treating impending miscarriages is still debatable. This narrative review aimed to evaluate the effectiveness of progesterone for pregnant women who are at risk of miscarriage. The effectiveness of progesterone were obtained from online database publications as PubMed, EBSCOhost, and Google Scholar between 2019 and 2024. The search was conducted by entering keywords in the database. Then by screening titles, abstracts, and contents, the search result obtained 15 articles. The outcomes were miscarriage, preterm birth, and live birth. Eight RCTs, 1 cohort, 5 meta-analyses, and 1 systematic review were included in this narrative review. The RCTs reviewed, revealed several journals which mention that oral, vaginal, and placebo progesterone have not significantly differed in preventing miscarriage. However, there were RCTs journal mention that oral dydrogesterone, vaginal and oral progesterone are effective in preventing miscarriage. In contrast, a meta-analysis research indicated that oral progesterone, vaginal progesterone, and dydrogesterone were all effective in reducing miscarriage. Progesterone supplementation may be effective in women at risk of miscarriage. The recommended route of progesterone treatment to threatened miscarriage is still controversial, but based on this narrative review, the vaginal route of progesterone is more effective and safer than oral route.
References
Mouri MI, Hall H, Rupp TJ. Threatened miscarriage. In: StatPearls. Treasure Island (FL): StatPearls Publishing 2024.
https://www.ncbi.nlm.nih.gov/books/NBK430747/
Tulandi T, Al-Fozan. Recurrent pregnancy loss: management. UpToDate. Retrieved January 04,2024.
https://uptodate.com/contents/recurrent-pregnacy-loss-management.
The American College of Obstetricians and Gynecologists ACOG, Practice Bulletin no. 150. Early pregnancy loss. Obstet Gynecol 2015; 125(5):1258-67.
https://doi.org/10.1097/01.AOG.0000465191.27155.25
Ferrari R. Writing narrative literature reviews. Medical Writing 2015; 24(4):230-5.
https://doi.org/10.1179/2047480615Z.000000000329
Coomarasamy A, Devall AJ, Cheed V, Harb H, Middleton LJ, Gallos ID, et al. A randomized trial of progesterone in women with bleeding in early pregnancy. N Engl J Med 2019; 380(19):1815-24.
https://doi.org/10.1056/NEJMoa1813730
Chan DMK, Cheung KW, Ko JKY, Yung SSF, Lai SF, Lam MT, et al. Use of oral progestogen in women with threatened miscarriage in the first trimester: a randomized double-blind controlled trial. Hum Reprod 2021; 36(3):587-95.
https://doi.org/10.1093/humrep/deaa327
Coomarasamy A, Harb HM, Devall AJ, Cheed V, Roberts TE, Goranitis I, et al. Progesterone to prevent miscarriage in women with early pregnancy bleeding: the PRISM RCT. Health Technol Assess 2020; 24(33):1-70.
https://doi.org/10.3310/hta24330
Kale AR, Ashwini AK, Kanan YA. Comparative, randomized control trial in patients of per vaginal bleeding comparing efficacy of oral dydrogesterone versus vaginal progesterone in successful pregnancy outcome for patients with recurrent pregnancy loss. J Obstet Gynecol India 2021; 71(6):591-5.
https://doi.org/10.1007/s13224-021-01473-2
Parveen R, Khakwani M, Tabassum S, Masood S. Oral versus vaginal micronized progesterone for the treatment of threatened miscarriage. Pak J Med Sci 2021; 37(3):628-32.
https://doi.org/10.12669/pjms.37.3.3700
McLindon LA, James G, Beckmann MM, Bertolone J, Mahomed K, Vane M, et al. Progesterone for women with threatened miscarriage (STOP Trial): a placebo-controlled randomized clinical trial. Hum Reprod 2023; 38(4):560-8.
https://doi.org/10.1093/humrep/dead029
Kuptarak A, Vorapong P. Oral dydrogesterone for prevention of miscarriage in threatened miscarriage: a randomized, double-Blind, placebo controlled trial. J Matern Fetal Neonatal Med 2024; 37(1):2333929.
https://doi.org/10.1080/14767058.2024.2333929
Shinwari L, Afrah A, Mehwish S, Rabia N, Rehana R. Efficacy of oral versus vaginal progestogens for early pregnancy maintenance in women with recurrent miscarriages: a randomized controlled trial. Khyber Med Univ J 2024; 16(1):25-9.
https://doi.org/10.35845/kmuj.2024.22727
Lou C, Wang C, Zhao Q, Jin F. Effect of dydrogesterone and progesterone on threatened miscarriage due to corpus luteum insufficiency. Am J Transl Res 2021; 13(5):4544-52.
Haas DM, Hathaway TJ, Ramsey PS. Progestogen for preventing miscarriage in women with recurrent miscarriage of unclear etiology. Cochrane Database Syst Rev 2018; 10(10):CD003511.
https://doi.org/10.1002/14651858.CD003511.pub4
Devall AJ, Papadopoulou A, Podesek M, Haas DM, Price MJ, Coomarasamy A, et al. Progestogens for preventing miscarriage: a network meta-analysis. Cochrane Database Syst Rev 2021; 4(4):CD013792.
https://doi.org/10.1002/14651858.CD013792.pub2
Guo H, Lu Q. Efficacy of dydrogesterone on treating recurrent miscarriage and its influence on immune factors: a systematic review and meta-analysis. Ann Palliat Med 2021; 10(10):10971-85.
https://doi.org/10.21037/apm-21-2605
Yan Y, Chen Z, Yang Y, Zheng X, Zou M, Cheng G, et al. Efficacy of progesterone on threatened miscarriage: an updated meta-analysis of randomized trials. Arch Gynecol Obstet 2021; 303(1):27-36.
https://doi.org/10.1007/s00404-020-05808-8
Zhao Y, D'Souza R, Gao Y, Hao Q, Kallas-Silva L, Steen JP, et al. Progestogens in women with threatened miscarriage or recurrent miscarriage: a meta-analysis. Acta Obstet Gynecol Scand 2024; 103(9):1689-701.
https://doi.org/10.1111/aogs.14829
Li L, Zhang Y, Tan H, Bai Y, Fang F, Faramand A, et al. Effect of progestogen for women with threatened miscarriage: a systematic review and meta-analysis. BJOG 2020; 127(9):1055-63.
https://doi.org/10.1111/1471-0528.16261
Tangco K, Sigue AJ, Gorgonio N. EP28.24: Corpus luteum of pregnancy: prognostic significance of the transvaginal ultrasound morphology and volume in early pregnancy outcome. Ultrasound Obstet Gynecol 2019; 54(S1):416-7.
https://doi.org/10.1002/uog.21713
Ashley E, Jorge D, Edgar R. Role of progesterone, estradiol and oxytocin hormones in myometrial fuction during pregnancy and labor. Perinatol Reprod Hum 2023; 37(1):31-8.
https://doi.org/10.24875/per.22000013
Arab H, Alharbi AJ, Oraif A, Sagr E, Al Madani H, Abduljabbar H, et al. The role of progestogens in threatened and idiopathic recurrent miscarriage. Int J Womens Health 2019; 7(11):589-96.
https://doi.org/10.2147/IJWH.S224159
EPPPIC Group. Evaluating Progestogens for Preventing Preterm Birth International Collaborative (EPPPIC): meta-analysis of individual participant data from randomized controlled trials. Lancet 2021; 397(10280):1183-94.
https://doi.org/10.1016/S0140-6736(21)00217-8
Shah NM, Lai PF, Imami N, Johnson MR. Progesterone-related immune modulation of pregnancy and labor. Front Endocrinol (Lausanne) 2019; 10:198.
https://doi.org/10.3389/fendo.2019.00198
Marquardt RM, Kim TH, Shin JH, Jeong JW. Progesterone and estrogen signaling in the endometrium: what goes wrong in endometriosis? Int J Mol Sci 2019; 20(15):3822.
https://doi.org/10.3390/ijms20153822
Bulletti C, Bulletti FM, Sciorio R, Guido M. Progesterone: The key factor of the beginning of life. Int J Mol Sci 2022; 23(22):14138.
https://doi.org/10.3390/ijms232214138
Nadarajah R, Rajesh H, Wong KY, Faisal F, Yu SL. Live birth rates and safety profile using dydrogesterone for luteal phase support in assisted reproductive techniques. Singapore Med J 2017; 58(6):294-7.
https://doi.org/10.11622/smedj.2016080
Bryce C. Treatment of threatened miscarriage with progestogens. Am Fam Physician 2019; 100(5):279-80.
Paulson RJ, Collins MG, Yankov VI. Progesterone pharmacokinetics and pharmacodynamics with 3 dosages and 2 regimens of an effervescent micronized progesterone vaginal insert. J Clin Endocrinol Metab 2014; 99(11):4241-9.
